The lack of selectivity and sufficient delivery of the current anticancer agents in use is a major cause of severe side effects and treatment failures. Our approach is to use zirconium phosphate (ZrP) nanoplatelet, an inorganic layered nanoparticle, for targeted delivery of anticancer drugs to cancer cells and control release of drugs inside the cells in response to the endosome microenvironment. ZrP platelet shape is particularly important for nanoparticles to deliver anticancer drugs to tumors as it can overcome some of the disadvantages of spherically shaped nanoparticles. ZrP are themselves non-toxic to human cells and can intercalate high load of many different anti-cancer drugs between their layers. We have illustrated this assertion by placing high levels of doxorubicin (DOX) within the layers. In-vitro studies with DOX@ZrP in breast cancer cell line (MCF-7) showed a 50-fold death of the cells after 48 hours of incubation, compared with only doxorubicin.

BTHO cancer: Novel inorganic layered nanoplatelets for drug delivery in cancer nanotherapy

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.